A novel therapeutic mechanism for mesenchymal stem cells to alleviate oxidative stress in Alzheimer's disease

doi:10.3877/cma.j.issn.2095-1221.2024.02.005

Abstract

Abstract:

Alzheimer's disease (AD) is the leading cause of age-related dementia, which is characterized by progressive brain atrophy and cognitive dysfunction, ultimately leading to an inability to care for oneself. Although some pharmacologic treatments may alleviate AD symptoms, they do not halt the progression of AD and have multiple side effects. Based on the hypothesis that there are multiple pathogenic mechanisms in AD, and the progression of AD is affected by more than a single condition. Recently, the oxidative stress microenvironment in the brain has attracted much attention. Mesenchymal stem cells (MSCs) improve the microenvironment of the brain due to their multiple regulatory roles, such as immune regulation, anti-inflammation, regeneration, antioxidant, anti-apoptosis, and neuroprotection, which reduce pathological changes of AD and thus reduce its effects. MSCs, especially dental pulp stem cells (DPSCs) , not only secrete neuroprotective and anti- inflammatory factors to promote neuronal survival but also promote the accumulation of microglia around protein aggregates, remove pathological aggregates, and alleviate mitochondrial damage. This review focuses on using MSCs and potential MSCs cellular resources DPSCs to slow down AD development by improving the oxidative stress microenvironment, providing new ideas for treating AD in the clinic.

Key words: Alzheimer's disease, Mesenchymal stem cells, Dental pulp stem cells, Oxidative stress, Reactive oxygen species

Juan Wang, Ye Liu, Wei Xiong, Cailei Jiang, Yan He, Qingsong Ye. A novel therapeutic mechanism for mesenchymal stem cells to alleviate oxidative stress in Alzheimer's disease[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(02): 93-106.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2024.02.005

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2024/V14/I02/93

Figures/Tables 7

References 161

1	Jorfi M, Maaser-Hecker A, Tanzi RE. The neuroimmune axis of Alzheimer's disease[J]. Genome Med, 2023, 15(1):6. doi: 10.1186/s13073-023-01155-w.
2	Zhang Y, Chen H, Li R, et al. Amyloid β-based therapy for Alzheimer's disease:challenges, successes and future[J]. Signal Transduct Target Ther, 2023, 8(1):248. doi: 10.1038/s41392-023-01484-7.
3	Zhang H, Wei W, Zhao M, et al. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease[J]. Int J Biol Sci, 2021, 17(9):2181-2192.
4	Xiong W, Liu Y, Zhou H, et al. Alzheimer's disease: pathophysiology and dental pulp stem cells therapeutic prospects[J]. Front Cell Dev Biol, 2022, 10:999024. doi: 10.3389/fcell.2022.999024.
5	Dewanjee S, Chakraborty P, Bhattacharya H, et al. Altered glucose metabolism in Alzheimer's disease: role of mitochondrial dysfunction and oxidative stress[J]. Free Radic Biol Med, 2022, 193(Pt 1):134-157.
6	Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease[J]. Nat Rev Neurosci, 2019, 20(3):148-160.
7	Huang WJ, Zhang X, Chen WW. Role of oxidative stress in Alzheimer's disease[J]. Biomed Rep, 2016, 4(5):519-522.
8	Park MW, Cha HW, Kim J, et al. NOX4 promotes ferroptosis of astrocytes by oxidative stress-induced lipid peroxidation via the impairment of mitochondrial metabolism in Alzheimer's diseases[J]. Redox Biol, 2021, 41:101947. doi: 10.1016/j.redox.2021.101947.
9	Andrzejewska A, Dabrowska S, Lukomska B, et al. Mesenchymal stem cells for neurological disorders[J]. Adv Sci (Weinh), 2021, 8(7):2002944. doi: 10.1002/advs.202002944.
10	Sivandzade F, Cucullo L. Regenerative stem cell therapy for neurodegenerative diseases: an overview[J]. Int J Mol Sci, 2021, 22(4): 2153. doi:10.3390/ijms22042153.
11	Jia Y, Cao N, Zhai J, et al. HGF mediates clinical-grade human umbilical cord-derived mesenchymal stem cells improved functional recovery in a senescence-accelerated mouse model of Alzheimer's disease[J]. Adv Sci (Weinh), 2020, 7(17):1903809. doi:10.1002/advs.201903809.
12	Santamaria G, Brandi E, Vitola P, et al. Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer's mice[J]. Cell Death Differ, 2021, 28(1):203-218.
13	Zhang XM, Ouyang YJ, Yu BQ, et al. Therapeutic potential of dental pulp stem cell transplantation in a rat model of Alzheimer's disease[J]. Neural Regen Res, 2021, 16(5):893-898.
14	Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission[J]. Lancet, 2020, 396(10248):413-446.
15	Ahmadi-Abhari S, Guzman-Castillo M, Bandosz P, et al. Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study[J]. BMJ, 2017, 358: j2856. doi: 10.1136/bmj.j2856.
16	Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting the global burden of Alzheimer's disease[J]. Alzheimers Dement, 2007, 3(3):186-191.
17	Leone M, Kuja-Halkola R, Leval A, et al. Association of youth depression with subsequent somatic diseases and premature death[J]. JAMA Psychiatry, 2021, 78(3):302-310.
18	Ben Hassen C, Fayosse A, Landré B, et al. Association between age at onset of multimorbidity and incidence of dementia: 30 year follow-up in Whitehall Ⅱ prospective cohort study[J]. BMJ, 2022, 376:e068005. doi: 10.1136/bmj-2021-068005.
19	Sabia S, Singh-Manoux A. Healthy lifestyles for dementia prevention[J]. BMJ, 2023, 380:117. doi: 10.1136/bmj.p117.
20	Lisko I, Kulmala J, Annetorp M, et al. How can dementia and disability be prevented in older adults: where are we today and where are we going?[J]. J Intern Med, 2021, 289(6):807-830.
21	Bian Y, Chen Y, Wang X, et al. Oxyphylla A ameliorates cognitive deficits and alleviates neuropathology via the Akt-GSK3β and Nrf2-Keap1-HO-1 pathways in vitro and in vivo murine models of Alzheimer's disease[J]. J Adv Res, 2021, 34:1-12.
22	Harman D. Aging: a theory based on free radical and radiation chemistry[J]. J Gerontol, 1956, 11(3):298-300.
23	Wang X, Michaelis EK. Selective neuronal vulnerability to oxidative stress in the brain[J]. Front Aging Neurosci. 2010, 2:12. doi: 10.3389/fnagi.2010.00012.
24	Cenini G, Lloret A, Cascella R. Oxidative stress in neurodegenerative diseases: from a mitochondrial point of view[J]. Oxid Med Cell Longev, 2019, 2019:2105607. doi: 10.1155/2019/2105607.
25	Mecocci P, Boccardi V, Cecchetti R, et al. A long journey into aging, brain aging, and Alzheimer's disease following the oxidative stress tracks[J]. J Alzheimers Dis, 2018, 62(3):1319-1335.
26	Jomova K, Vondrakova D, Lawson M, et al. Metals, oxidative stress and neurodegenerative disorders[J]. Mol Cell Biochem, 2010, 345(1- 2): 91-104.
27	Fukuyama R, Nakayama A, Nakase T, et al. A newly established neuronal rho-0 cell line highly susceptible to oxidative stress accumulates iron and other metals. Relevance to the origin of metal ion deposits in brains with neurodegenerative disorders[J]. J Biol Chem, 2002, 277(44):41455-41462.
28	Han Y, Gao C, Wang H, et al. Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice[J]. Bioact Mater, 2021, 6(2):529-542.
29	Jomova K, Raptova R, Alomar SY, et al. Reactive oxygen species, toxicity, oxidative stress, and antioxidants:chronic diseases and aging[J]. Arch Toxicol, 2023, 97(10):2499-2574.
30	Angelova PR, Abramov AY. Role of mitochondrial ROS in the brain: from physiology to neurodegeneration[J]. FEBS Lett, 2018, 592(5): 692-702.
31	Han S, Zhang M, Jeong YY, et al. The role of mitophagy in the regulation of mitochondrial energetic status in neurons[J]. Autophagy. 2021, 17(12):4182-4201.
32	Bahn G, Park JS, Yun UJ, et al. NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer's models[J]. Proc Natl Acad Sci U S A, 2019, 116(25):12516-12523.
33	Liao S, Wu J, Liu R, et al. A novel compound DBZ ameliorates neuroinflammation in LPS-stimulated microglia and ischemic stroke rats: Role of Akt(Ser473)/GSK3β(Ser9)-mediated Nrf2 activation[J]. Redox Biol, 2020, 36:101644. doi: 10.1016/j.redox.2020.101644.
34	Dinkova-Kostova AT, Copple IM. Advances and challenges in therapeutic targeting of NRF2[J]. rends Pharmacol Sci, 2023, 44(3): 137-149.
35	Osama A, Zhang J, Yao J, et al. Nrf2: a dark horse in Alzheimer's disease treatment[J]. Ageing Res Rev, 2020, 64:101206. doi: 10.1016/j.arr.2020.101206.
36	Fragoulis A, Siegl S, Fendt M, et al. Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease[J]. Redox Biol, 2017, 12:843-853.
37	Cheng L, Zhang W. DJ-1 affects oxidative stress and pyroptosis in hippocampal neurons of Alzheimer's disease mouse model by regulating the Nrf2 pathway[J]. Exp Ther Med, 2021, 21(6):557. doi: 10.3892/etm.2021.9989.
38	She L, Xiong L, Li L, et al. Ginsenoside Rk3 ameliorates Aβ-induced neurotoxicity in APP/PS1 model mice via AMPK signaling pathway[J]. Biomed Pharmacother, 2023, 158:114192. doi:10.1016/j.biopha.2022.114192.
39	Ren J, Zhang S, Wang X, et al. MEF2C ameliorates learning, memory, and molecular pathological changes in Alzheimer’s disease in vivo and in vitro[J]. Acta Biochim Biophys Sin (Shanghai), 2022, 54(1):77-90.
40	Wu YH, Hsieh HL. Roles of heme oxygenase-1 in neuroinflammation and brain disorders[J]. Antioxidants (Basel). 2022, 11(5):923. doi: 10.3390/antiox11050923.
41	Barone E, Di Domenico F, Sultana R, et al. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment[J]. Free Radic Biol Med, 2012, 52(11-12):2292-2301.
42	Cao K, Xiang J, Dong YT, et al. Activation of α7 nicotinic acetylcholine receptor by its selective agonist improved learning and memory of amyloid precursor protein/presenilin 1 (APP/PS1) mice via the Nrf2/HO-1 pathway[J]. Med Sci Monit, 2022, 28:e933978. doi:10.12659/MSM.933978.
43	Tarafdar A, Pula G. The role of NADPH oxidases and oxidative stress in neurodegenerative disorders[J]. Int J Mol Sci, 2018, 19(12):3824. doi:10.3390/ijms19123824.
44	Tao W, Yu L, Shu S, et al. miR-204-3p/Nox4 mediates memory deficits in a mouse model of Alzheimer's disease[J]. Mol Ther, 2021, 29(1):396-408.
45	Malkov A, Popova I, Ivanov A, et al. Aβ initiates brain hypometabolism, network dysfunction and behavioral abnormalities via NOX2-induced oxidative stress in mice[J]. Commun Biol, 2021, 4(1):1054. doi: 10.1038/s42003-021-02551-x.
46	Nguyen TPN, Kumar M, Fedele E, et al. MicroRNA alteration, application as biomarkers, and therapeutic approaches in neurodegenerative diseases[J]. Int J Mol Sci, 2022, 23(9):4718. doi: 10.3390/ijms23094718.
47	Liu S, Fan M, Zheng Q, et al. MicroRNAs in Alzheimer's disease: Potential diagnostic markers and therapeutic targets[J]. Biomed Pharmacother, 2022, 148:112681. doi: 10.1016/j.biopha.2022.112681.
48	Meng S, Wang B, Li W. CircAXL knockdown alleviates Aβ(1-42)-induced neurotoxicity in Alzheimer's disease via repressing PDE4A by releasing miR-1306-5p[J]. Neurochem Res, 2022, 47(6):1707-1720.
49	Duan W, Chen X. Jatrorrhizine can improve nerve cell injury induced by Aβ 25-35, acting through miR-223-3p/HDAC4 axis[J]. Am J Transl Res, 2021, 13(5):4644-4655.
50	Zhang YY, Bao HL, Dong LX, et al. Silenced lncRNA H19 and up- regulated microRNA-129 accelerates viability and restrains apoptosis of PC12 cells induced by Aβ(25-35) in a cellular model of Alzheimer's disease[J]. Cell cycle, 2021, 20(1):112-125.
51	Li S, Wu L, Ma M, et al. MicroRNA-668-3p regulates oxidative stress and cell damage induced by Aβ1-42 by targeting the OXR1/p53-p21 axis[J]. Ann Transl Med, 2022, 10(17):928. doi: 10.21037/atm-22-3598.
52	Lei B, Liu J, Yao Z, et al. NF-κB-induced upregulation of miR-146a- 5p promoted hippocampal neuronal oxidative stress and pyroptosis via TIGAR in a model of Alzheimer's disease[J]. Front Cell Neurosci, 2021, 15:653881. doi: 10.3389/fncel.2021.653881.
53	Azman KF, Zakaria R. Recent advances on the role of brain-derived neurotrophic factor (BDNF) in neurodegenerative diseases[J]. Int J Mol Sci, 2022, 23(12):6827. doi: 10.3390/ijms23126827.
54	Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease[J]. Nat Med, 2009, 15(3):331-337.
55	Kang T, Qu Q, Xie Z, et al. NDRG4 alleviates Aβ1-40 induction of SH-SY5Y cell injury via activation of BDNF-inducing signalling pathways[J]. Neurochem Res. 2020, 45(7):1492-1499.
56	Huang CC, Chang KH, Chiu YJ, et al. Multi-target effects of novel synthetic coumarin derivatives protecting Aβ-GFP SH-SY5Y cells against Aβ toxicity[J]. Cells, 2021, 10(11):3095. doi: 10.3390/cells10113095.
57	Li F, Wu X, Li J, et al. Ginsenoside Rg1 ameliorates hippocampal long- term potentiation and memory in an Alzheimer's disease model[J]. Mol Med Rep, 2016, 13(6):4904-4910.
58	Lv J, Lu C, Jiang N, et al. Protective effect of ginsenoside Rh2 on scopolamine-induced memory deficits through regulation of cholinergic transmission, oxidative stress and the ERK-CREB-BDNF signaling pathway[J]. Phytother Res, 2021, 35(1):337-345.
59	Yan T, He B, Xu M, et al. Kaempferide prevents cognitive decline via attenuation of oxidative stress and enhancement of brain- derived neurotrophic factor/tropomyosin receptor kinase B/cAMP response element-binding signaling pathway[J]. Phytother Res, 2019, 33(4): 1065-1073.
60	Liu Y, Nguyen M, Robert A, et al. Metal ions in Alzheimer's disease: akey role or not?[J]. Acc Chem Res, 2019, 52(7):2026-2035.
61	Wärmländer S, Österlund N, Wallin C, et al. Metal binding to the amyloid-β peptides in the presence of biomembranes: potential mechanisms of cell toxicity[J]. J Biol Inorg Chem, 2019, 24(8):1189-1196.
62	Duce JA, Bush AI. Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics[J]. Prog Neurobiol, 2010, 92(1):1-18.
63	Simunkova M, Alwasel SH, Alhazza IM, et al. Management of oxidative stress and other pathologies in Alzheimer's disease[J]. Arch Toxicol, 2019, 93(9):2491-2513.
64	Poprac P, Jomova K, Simunkova M, et al. Targeting free radicals in oxidative stress-related human diseases[J]. Trends Pharmacol Sci, 2017, 38(7):592-607.
65	Bai R, Guo J, Ye XY, et al. Oxidative stress: the core pathogenesis and mechanism of Alzheimer's disease[J]. Ageing Res Rev, 2022, 77:101619. doi: 10.1016/j.arr.2022.101619.
66	Ma C, Hong F, Yang S. Amyloidosis in Alzheimer's disease: pathogeny, etiology, and related therapeutic directions[J]. Molecules, 2022, 27(4):1210. doi: 10.3390/molecules27041210.
67	Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid[J]. Mol Neurodegener, 2006, 1:5. doi: 10.1186/1750-1326-1-5.
68	Bhattacharyya R, Teves CAF, Long A, et al. The neuronal-specific isoform of BIN1 regulates β-secretase cleavage of APP and Aβ generation in a RIN3-dependent manner[J]. Sci Rep, 2022, 12(1):3486. doi:10.1038/s41598-022-07372-4.
69	Ulku I, Liebsch F, Akerman SC, et al. Mechanisms of amyloid-β34 generation indicate a pivotal role for BACE1 in amyloid homeostasis[J]. Sci Rep, 2023, 13(1):2216. doi: 10.1038/s41598-023-28846-z.
70	Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein[J]. Biochem Biophys Res Commun, 1984, 120(3):885-890.
71	Hardy JA, Higgins GA. Alzheimer's disease:the amyloid cascade hypothesis[J]. Science, 1992, 256(5054):184-185.
72	Rubin R. Much anticipated Alzheimer disease prevention trial finds no clinical benefit from drug targeting amyloid; highlights need to consider other approaches[J]. Jama, 2022, 328(10):907-910.
73	Hassan W, Noreen H, Rehman S, et al. Association of oxidative stress with neurological disorders[J]. Curr Neuropharmacol, 2022, 20(6): 1046-1072.
74	Steinert JR, Amal H. The contribution of an imbalanced redox signalling to neurological and neurodegenerative conditions[J]. Free Radic Biol Med, 2023, 194:71-83.
75	Shadfar S, Parakh S, Jamali MS, et al. Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases[J]. Transl Neurodegener, 2023, 12(1):18. doi:10.1186/s40035-023-00350-4.
76	Perluigi M, Di Domenico F, Butterfield DA. Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease[J]. Physiol Rev, 2024, 104(1):103-197.
77	Wang P, Wang ZY. Metal ions influx is a double edged sword for the pathogenesis of Alzheimer's disease[J]. Ageing Res Rev, 2017, 35:265-290.
78	Everett J, Lermyte F, Brooks J, et al. Biogenic metallic elements in the human brain?[J]. Sci Adv, 2021, 7(24):eabf6707. doi: 10.1126/sciadv.abf6707.
79	Lee JY, Mook-Jung I, Koh JY. Histochemically reactive zinc in plaques of the swedish mutant beta-amyloid precursor protein transgenic mice[J].J Neurosci, 1999, 19(11):Rc10.
80	Smith MA, Harris PL, Sayre LM, et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals[J]. Proc Natl Acad Sci U S A, 1997, 94(18):9866-9868.
81	Vejux A. Cell death, inflammation and oxidative stress in neurodegenerative diseases: mechanisms and cytoprotective molecules[J]. Int J Mol Sci, 2021, 22(24):13657. doi: 10.3390/ijms222413657.
82	Devine MJ, Kittler JT. Mitochondria at the neuronal presynapse in health and disease[J]. Nat Rev Neurosci, 2018, 19(2):63-80.
83	Guo L, Tian J, Du H. Mitochondrial dysfunction and synaptic transmission failure in Alzheimer's disease[J]. J Alzheimers Dis, 2017, 57(4):1071-1086.
84	Lee HJ, Jung YH, Choi GE, et al. Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis[J]. Cell Death Differ, 2021, 28(1):184-202.
85	Uttara B, Singh AV, Zamboni P, et al. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options[J]. Curr Neuropharmacol, 2009, 7(1):65-74.
86	Quintana DD, Garcia JA, Anantula Y, et al. Amyloid-β causes mitochondrial dysfunction via a Ca²⁺-driven upregulation of oxidative phosphorylation and superoxide production in cerebrovascular endothelial cells[J]. J Alzheimers Dis, 2020, 75(1):119-138.
87	Fragoso-Morales LG, Correa-Basurto J, Rosales-Hernández MC. Implication of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and its inhibitors in Alzheimer's disease murine models[J]. Antioxidants (Basel), 2021, 10(2):218. doi: 10.3390/antiox10020218.
88	Ganguly U, Kaur U, Chakrabarti SS, et al. Oxidative stress, neuroinflammation, and NADPH oxidase: implications in the pathogenesis and treatment of Alzheimer's disease[J]. Oxid Med Cell Longev, 2021, 2021:7086512. doi: 10.1155/2021/7086512.
89	Liu Z, Zhou T, Ziegler AC, et al. Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications[J]. Oxid Med Cell Longev, 2017, 2017:2525967. doi: 10.1155/2017/2525967.
90	Eckel BD, Cruz R, Jr., Craig EM, et al. Microtubule polarity flaws as a treatable driver of neurodegeneration[J]. Brain Res Bull, 2023, 192:208-215.
91	Higuchi M, Lee VM, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders[J]. Neuromolecular Med, 2002, 2(2):131-150.
92	DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease[J]. Mol Neurodegener, 2019, 14(1):32. doi: 10.1186/s13024-019-0333-5.
93	Dumont M, Stack C, Elipenahli C, et al. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice[J]. FASEB J, 2011, 25(11):4063-4072.
94	Gómez-Ramos A, Díaz-Nido J, Smith MA, et al. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells[J]. J Neurosci Res, 2003, 71(6):863-870.
95	Giraldo E, Lloret A, Fuchsberger T, et al. Aβ and tau toxicities in Alzheimer's are linked via oxidative stress-induced p38 activation: protective role of vitamin E[J]. Redox Biol, 2014, 2:873-877.
96	Su B, Wang X, Lee HG, et al. Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells[J]. Neurosci Lett, 2010, 468(3):267-271.
97	Stamer K, Vogel R, Thies E, et al. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress[J]. J Cell Biol, 2002, 156(6):1051-1063.
98	Du F, Yu Q, Kanaan NM, et al. Mitochondrial oxidative stress contributes to the pathological aggregation and accumulation of Tau oligomers in Alzheimer's disease[J]. Hum Mol Genet, 2022, 31(15):2498-2507.
99	Simpson DSA, Oliver PL. ROS generation in microglia: understanding oxidative stress and inflammation in neurodegenerative disease[J]. Antioxidants (Basel), 2020, 9(8):743. doi: 10.3390/antiox9080743.
100	Esteras N, Kundel F, Amodeo GF, et al. Insoluble tau aggregates induce neuronal death through modification of membrane ion conductance, activation of voltage-gated calcium channels and NADPH oxidase[J]. FEBS J, 2021, 288(1):127-141.
101	Ganguly G, Chakrabarti S, Chatterjee U, et al. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease[J]. Drug Des Devel Ther, 2017, 11:797-810.
102	Kandimalla R, Manczak M, Yin X, et al. Hippocampal phosphorylated tau induced cognitive decline, dendritic spine loss and mitochondrial abnormalities in a mouse model of Alzheimer's disease[J]. Hum Mol Genet, 2018, 27(1):30-40.
103	Althafar ZM. Targeting microglia in Alzheimer's disease: from molecular mechanisms to potential therapeutic targets for small molecules[J]. Molecules, 2022, 27(13):4124. doi:10.3390/molecules27134124.
104	Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease[J]. J Neuropathol Exp Neurol, 2001, 60(8):759-767.
105	Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease[J]. Lancet Neurol, 2015, 14(4):388-405.
106	Khan S, Barve KH, Kumar MS. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease[J]. Curr Neuropharmacol, 2020, 18(11):1106-1125.
107	Doens D, Fernández PL. Microglia receptors and their implications in the response to amyloid β for Alzheimer's disease pathogenesis[J]. J Neuroinflammation, 2014, 11:48. doi: 10.1186/1742-2094-11-48.
108	Bennett ML, Viaene AN. What are activated and reactive glia and what is their role in neurodegeneration?[J]. Neurobiol Dis, 2021, 148:105172. doi: 10.1016/j.nbd.2020.105172.
109	Hanslik KL, Marino KM, Ulland TK. Modulation of glial function in health, aging, and neurodegenerative disease[J]. Front Cell Neurosci, 2021, 15:718324. doi: 10.3389/fncel.2021.718324.
110	Choi SS, Lee SR, Lee HJ. Neurorestorative role of stem cells in Alzheimer's disease: astrocyte involvement[J]. Curr Alzheimer Res, 2016, 13(4):419-427.
111	Elangovan S, Holsinger RMD. Cyclical amyloid beta-astrocyte activity induces oxidative stress in Alzheimer's disease[J]. Biochimie, 2020, 171-172:38-42.
112	Novoa C, Salazar P, Cisternas P, et al. Inflammation context in Alzheimer's disease, a relationship intricate to define[J]. Biol Res, 2022, 55(1):39. doi: 10.1186/s40659-022-00404-3.
113	Li J, Chen L, Liu S, et al. Hydrocortisone mitigates Alzheimer's-related cognitive decline through modulating oxidative stress and neuroinflammation[J]. Cells, 2023, 12(19):2348. doi: 10.3390/cells12192348.
114	Briggs R, Kennelly SP, O'Neill D. Drug treatments in Alzheimer's disease[J]. Clin Med (Lond), 2016, 16(3):247-253.
115	van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease[J]. N Engl J Med, 2023, 388(1):9-21.
116	Söderberg L, Johannesson M, Nygren P, et al. Lecanemab, aducanumab, and gantenerumab-binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease[J]. Neurotherapeutics, 2023, 20(1):195-206.
117	Friedenstein AJ, Piatetzky S, Ⅱ, Petrakova KV. Osteogenesis in transplants of bone marrow cells[J]. J Embryol Exp Morphol, 1966, 16(3):381-390.
118	Andrzejewska A, Lukomska B, Janowski M. Concise review: mesenchymal stem cells: from roots to boost[J]. Stem Cells, 2019, 37(7):855-864.
119	Uccelli A, Benvenuto F, Laroni A, et al. Neuroprotective features of mesenchymal stem cells[J]. Best Pract Res Clin Haematol, 2011, 24(1):59-64.
120	Babaei H, Kheirollah A, Ranjbaran M, et al. Dose-dependent neuroprotective effects of adipose-derived mesenchymal stem cells on amyloid β-induced Alzheimer's disease in rats[J]. Biochem Biophys Res Commun, 2023, 678:62-67.
121	Kim HJ, Cho KR, Jang H, et al. Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial[J]. Alzheimers Res Ther, 2021, 13(1):154. doi: 10.1186/s13195-021-00897-2.
122	Nakano M, Kubota K, Kobayashi E, et al. Bone marrow-derived mesenchymal stem cells improve cognitive impairment in an Alzheimer's disease model by increasing the expression of microRNA-146a in hippocampus[J]. Sci Rep, 2020, 10(1):10772. doi:10.1038/s41598-020-67460-1.
123	Si Z, Wang X. Stem cell therapies in Alzheimer's disease: applications for disease modeling[J]. J Pharmacol Exp Ther, 2021, 377(2):207-217.
124	Neves AF, Camargo C, Premer C, et al. Intravenous administration of mesenchymal stem cells reduces Tau phosphorylation and inflammation in the 3xTg-AD mouse model of Alzheimer's disease[J]. Exp Neurol, 2021, 341:113706. doi:10.1016/j.expneurol.2021.113706.
125	Lee NK, Park SE, Kwon SJ, et al. Agouti related peptide secreted via human mesenchymal stem cells upregulates proteasome activity in an Alzheimer's disease model[J]. Sci Rep, 2017, 7:39340. doi:10.1038/srep39340.
126	Kim DW, Tu KJ, Wei A, et al. Amyloid-beta and tau pathologies act synergistically to induce novel disease stage-specific microglia subtypes[J]. Mol Neurodegener, 2022, 17(1):83. doi: 10.1186/s13024-022-00589-x.
127	Razavi S, Razavi MR, Zarkesh Esfahani H, et al. Comparing brain-derived neurotrophic factor and ciliary neurotrophic factor secretion of induced neurotrophic factor secreting cells from human adipose and bone marrow-derived stem cells[J]. Dev Growth Differ, 2013, 55(6):648-655.
128	Song MS, Learman CR, Ahn KC, et al. In vitro validation of effects of BDNF-expressing mesenchymal stem cells on neurodegeneration in primary cultured neurons of APP/PS1 mice[J]. Neuroscience, 2015, 307:37-50.
129	Kaniowska D, Wenk K, Rademacher P, et al. Extracellular vesicles of mesenchymal stromal cells can be taken up by microglial cells and partially prevent the stimulation induced by β-amyloid[J]. Stem Cell Rev Rep, 2022, 18(3):1113-1126.
130	Hasanpour M, Rahbarghazi R, Nourazarian A, et al. Conditioned medium from amniotic fluid mesenchymal stem cells could modulate Alzheimer's disease-like changes in human neuroblastoma cell line SY-SY5Y in a paracrine manner[J]. Tissue Cell, 2022, 76:101808. doi: 10.1016/j.tice.2022.101808.
131	Yokokawa K, Iwahara N, Hisahara S, et al. Transplantation of mesenchymal stem cells improves amyloid-β pathology by modifying microglial function and suppressing oxidative stress[J]. J Alzheimers Dis, 2019, 72(3):867-884.
132	Regmi S, Liu DD, Shen M, et al. Mesenchymal stromal cells for the treatment of Alzheimer's disease: Strategies and limitations[J]. Front Mol Neurosci, 2022, 15:1011225.
133	Zhan J, Li X, Luo D, et al. Polydatin promotes the neuronal differentiation of bone marrow mesenchymal stem cells in vitro and in vivo: Involvement of Nrf2 signalling pathway[J]. J Cell Mol Med, 2020, 24(9):5317-5329.
134	Jang S, Kang YH, Ullah I, et al. Cholinergic nerve differentiation of mesenchymal stem cells derived from long-term cryopreserved human dental pulp in vitro and analysis of their motor nerve regeneration potential in vivo[J]. Int J Mol Sci, 2018, 19(8):2434. doi: 10.3390/ijms19082434.
135	de Godoy MA, Saraiva LM, de Carvalho LRP, et al. Mesenchymal stem cells and cell-derived extracellular vesicles protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-β oligomers[J]. J Biol Chem, 2018, 293(6):1957-1975.
136	Bodart-Santos V, de Carvalho LRP, de Godoy MA, et al. Extracellular vesicles derived from human Wharton's jelly mesenchymal stem cells protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-β oligomers[J]. Stem Cell Res Ther, 2019, 10(1):332. doi: 10.1186/s13287-019-1432-5.
137	Wen C, Huang C, Yang M, et al. The secretion from bone marrow mesenchymal stem cells pretreated with berberine rescues neurons with oxidative damage through activation of the Keap1-Nrf2-HO-1 signaling pathway[J]. Neurotox Res, 2020, 38(1):59-73.
138	Lee HJ, Lee JK, Lee H, et al. The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer's disease[J]. Neurosci Lett, 2010, 481(1):30-35.
139	Yang H, Yue C, Yang H, et al. Intravenous administration of human umbilical cord mesenchymal stem cells improves cognitive impairments and reduces amyloid-beta deposition in an AβPP/PS1 transgenic mouse model[J]. Neurochem Res, 2013.doi: 10.1007/s11064-013-1161-6.
140	Aragón-González A, Shaw PJ, Ferraiuolo L. Blood-brain barrier disruption and its involvement in neurodevelopmental and neurodegenerative disorders[J]. Int J Mol Sci, 2022, 23(23):15271. doi: 10.3390/ijms232315271.
141	Alkhalifa AE, Al-Ghraiybah NF, Odum J, et al. Blood-brain barrier breakdown in Alzheimer's disease: mechanisms and targeted strategies[J]. Int J Mol Sci, 2023, 24(22):16288. doi:10.3390/ijms242216288.
142	Seo BM, Miura M, Sonoyama W, et al. Recovery of stem cells from cryopreserved periodontal ligament[J]. J Dent Res, 2005, 84(10):907-912.
143	Luo L, He Y, Wang X, et al. Potential roles of dental pulp stem cells in neural regeneration and repair[J]. Stem Cells Int, 2018, 2018:1731289. doi:10.1155/2018/1731289.
144	Honda M, Ohshima H. Biological characteristics of dental pulp stem cells and their potential use in regenerative medicine[J]. J Oral Biosci, 2022, 64(1):26-36.
145	Goorha S, Victor AK, Reiter LT. Culturing and neuronal differentiation of human dental pulp stem cells[J]. Curr Protoc, 2022, 2(11):e600. doi: 10.1002/cpz1.600.
146	Ahmed Nel M, Murakami M, Hirose Y, et al. Therapeutic potential of dental pulp stem cell secretome for Alzheimer's disease treatment: an in vitro study[J]. Stem Cells Int, 2016, 2016:8102478. doi:10.1155/2016/8102478.
147	Tripathy D, Thirumangalakudi L, Grammas P. RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role[J]. Neurobiol Aging, 2010, 31(1):8-16.
148	Religa P, Cao R, Religa D, et al. VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival[J]. Sci Rep, 2013, 3:2053. doi: 10.1038/srep02053.
149	Sanchez-Sanchez JL, Giudici KV, Guyonnet S, et al. Plasma MCP- 1 and changes on cognitive function in community-dwelling older adults[J]. Alzheimers Res Ther, 2022, 14(1):5. doi: 10.1186/s13195-021-00940-2.
150	Eugenín J, Eugenín-von Bernhardi L, von Bernhardi R. Age-dependent changes on fractalkine forms and their contribution to neurodegenerative diseases[J]. Front Mol Neurosci, 2023, 16:1249320. doi: 10.3389/fnmol.2023.1249320.
151	Panyard DJ, McKetney J, Deming YK, et al. Large-scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer's disease[J]. Alzheimers Dement, 2023, 19(12):5447-5470.
152	Boyd TD, Bennett SP, Mori T, et al. GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice[J]. J Alzheimers Dis, 2010, 21(2):507-18.
153	Wang F, Jia Y, Liu J, et al. Dental pulp stem cells promote regeneration of damaged neuron cells on the cellular model of Alzheimer's disease[J]. Cell Biol Int, 2017, 41(6):639-650.
154	Mishra M, Raik S, Rattan V, et al. Mitochondria transfer as a potential therapeutic mechanism in Alzheimer's disease-like pathology[J]. Brain Res, 2023, 1819:148544. doi: 10.1016/j.brainres.2023.148544.
155	Howlader MSI, Prateeksha P, Hansda S, et al. Secretory products of DPSC mitigate inflammatory effects in microglial cells by targeting MAPK pathway[J]. Pharmacother, 2024, 170:115971. doi: 10.1016/j.biopha.2023.115971.
156	Venugopal C, Shobha K, Rai KS, et al. Neurogenic and cognitive enhancing effects of human dental pulp stem cells and its secretome in animal model of hippocampal neurodegeneration[J]. Brain Res Bull, 2022, 180:46-58.
157	Mita T, Furukawa-Hibi Y, Takeuchi H, et al. Conditioned medium from the stem cells of human dental pulp improves cognitive function in a mouse model of Alzheimer's disease[J]. Behav Brain Res, 2015, 293:189-197.
158	赵志英,胡海涛,冯改丰,等.人脑源性神经营养因子基因修饰神经干细胞移植对痴呆大鼠学习记忆的改善[J].中国修复重建外科杂志, 2005, 19(5):331-334.
159	Hu W, Feng Z, Xu J, et al. Brain-derived neurotrophic factor modified human umbilical cord mesenchymal stem cells-derived cholinergic-like neurons improve spatial learning and memory ability in Alzheimer's disease rats[J]. Brain Res, 2019, 1710:61-73.
160	Wihadmadyatami H, Zulfikar MA, Herawati H, et al. Chitosan hydrogel nanoparticle enhance therapeutic effect of bovine umbilical mesenchymal stem cell conditioned medium on canine cognitive dysfunction or canine Alzheimer's like mediated by inhibition of neuronal apoptotic[J]. Open Vet J, 2023, 13(12):1504-1516.
161	Pollock K, Dahlenburg H, Nelson H, et al. Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington's disease mouse models[J]. Mol Ther, 2016, 24(5):965-977.

注册号	研究题目	开始时间/状态	阶段	国家
NCT02833792	异体人间质干细胞治疗阿尔茨海默病	2022-10/招募	Ⅱ期	美国
NCT02672306	阿尔茨海默病患者使用UCMSCs的安全性和探索性疗效研究	2018-04/未知	Ⅰ期	中国
NCT04040348	阿尔茨海默病：干细胞多次输注	2023-07/完成	Ⅰ期	美国
NCT01547689	脐带间充质干细胞（UC-MSC）在阿尔茨海默病患者中的安全性和有效性	2016-02/完成	Ⅰ/Ⅱ期	中国
NCT04228666	确定希望生物科学公司自体间充质干细胞疗法治疗阿尔茨海默病的安全性和有效性的临床试验	2021-07/终止	Ⅰ/Ⅱ期	美国
NCT01297218	阿尔茨海默病患者使用人脐带间充质干细胞的安全性和疗效评估	2012-04/完成	Ⅰ期	韩国

注册号	研究题目	开始时间/状态	阶段	国家
NCT02833792	异体人间质干细胞治疗阿尔茨海默病	2022-10/招募	Ⅱ期	美国
NCT02672306	阿尔茨海默病患者使用UCMSCs的安全性和探索性疗效研究	2018-04/未知	Ⅰ期	中国
NCT04040348	阿尔茨海默病：干细胞多次输注	2023-07/完成	Ⅰ期	美国
NCT01547689	脐带间充质干细胞（UC-MSC）在阿尔茨海默病患者中的安全性和有效性	2016-02/完成	Ⅰ/Ⅱ期	中国
NCT04228666	确定希望生物科学公司自体间充质干细胞疗法治疗阿尔茨海默病的安全性和有效性的临床试验	2021-07/终止	Ⅰ/Ⅱ期	美国
NCT01297218	阿尔茨海默病患者使用人脐带间充质干细胞的安全性和疗效评估	2012-04/完成	Ⅰ期	韩国

[1]	Yangkun Ding, Jiazhi Yu, Mingzhu Lu, Pengfei Mu, Xiangfei Liu, Tao Liu. Analysis of influencing factors of serum vitamin C level in children with acute hematogenous osteomyelitis [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(06): 689-695.
[2]	Wenfei Yang, Jiawen Hao, Mengyuan Lu, Xuegang Zhao, Congying Li, Chenyang Gai, Jing Zhang, Qingfu Zhang. Effects of high-voltage electrical burns on myocardial oxidative stress in rats and the intervention effect of N-acetylcysteine [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(02): 106-112.
[3]	Mengyuan Lu, Xuegang Zhao, Jiawen Hao, Chenyang Gai, Congying Li, Jing Zhang, Qingfu Zhang. Hepatic oxidative stress injury in high-voltage electrical burns rats and the intervention effect of brevisanthin [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(02): 113-118.
[4]	Shuxun Ling, Yue Tu, Siyi Liu. Visualization analysis on knowledge map of mesenchymal stem cells in the research field of chronic kidney disease [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(02): 73-82.
[5]	Jie Pei, Benliang Mao, Dingying Hao, Wei Yuan, Yong Yan, Fan Wu, Pengzhen Wang, Bailin Wang. Research progress and application of quercetin in regulating hepatic ischemia-reperfusion injury [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(02): 244-249.
[6]	Yabo Shi, Yang Li, Changwen Huang. Research advances in mechanism of the role of ischemia-reperfusion injury in promoting recurrence of hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(01): 96-99.
[7]	Le Li, Zhijun Zhu. Research progress of ferroptosis in liver ischemia-reperfusion injury [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(01): 109-113.
[8]	Jingxuan Shi, Yuanyuan Jiao, Jingwei Tian, Li Zhuo. Efficacy of mesenchymal stem cells-derived exosomes in the treatment of diabetic kidney disease in animals: a meta-analysis [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 79-86.
[9]	Zhangning Fu, Xiaodong Geng, Yongjun Zhang, Yuping Lu, Guannan Sun, Yifan Zhang, Guangyan Cai, Xiangmei Chen, Quan Hong. Research progress on the mechanism of mesenchymal stem cells in promoting renal injury repair [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 87-91.
[10]	Yifan Zhang, Xiaodong Geng, Yuwei Ji, Keying Zhang, Shupeng Lin, Guangyan Cai, Xiangmei Chen, Quan Hong. LRG1 enhanced the efficacy of mesenchymal stem cells in the treatment of acute kidney injury [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(01): 16-25.
[11]	Chunyu Tang, Qian Li, Shanshan Guo, Qi Ye, Dan Zhang. Characteristic of neurobiology in traumatic brain injury [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2023, 09(06): 367-371.
[12]	Meng Zhang, Zhonghua Yu. Expression of serum adiponectin, Lp-PLA2, IL-17 and correlation analysis with cognitive function in patients with Alzheimer's disease [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2023, 13(06): 358-363.
[13]	Lili Wang, Chunxia Zhang, Lei Shen, Lina Wu, Qing Pan, Xue Feng. Effects of mycophenolate mofetil combined with tripterygium glycosides and glucocorticoid on renal function, inflammatory factors, and oxidative stress in patients with IgA nephropathy [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(12): 1285-1290.
[14]	Minjie Zhang, Xiaoshan Zhang, Shasha Duan, Yilu Shi, Jie Zhao, Tianhao Bai, Yaxi Wang. Hydrogen for treatment of myocardial ischemia-reperfusion injury: mechanism and prospect [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 744-748.
[15]	Hanyan Xiao, Zijie Wang, Yue Wang, Yan Li. Quercetin against atherosclerosis by inhibiting pyroptosis of bone marrow-derived foam cells in mice [J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2024, 10(01): 26-32.

Please choose a citation manager

Content to export